Eliem Therapeutics Inc, a developer of therapies for neuronal excitability disorders, has secured $80 million in financing. The investors were RA Capital Management, Access Biotechnology and Intermediate Capital Group.
Source: Press Release
Eliem Therapeutics rallies $80m
Eliem Therapeutics Inc, a developer of therapies for neuronal excitability disorders, has secured $80 million in financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: